NATCOPHARM Stock View

Natco Pharma Ltd
stock-view-header

₹ 993.65

icon 20.30 | 2.04
Market Cap ₹( Cr.)
176,020.20
Proj. P/E (x)
13.78
Proj. P/BV (x)
3.07
Proj. ROE (%)
24.09
Proj EV / EBITDA (x)
--
Proj. Revenue ( Cr.)
38,693.00

Stock View

BUY

Last Updated On.
25-Feb-2024
 

The average score for Natco Pharma Ltd stands at 10 against 8, three months back.

Natco Pharma Limited is an India-based vertically integrated, research and development (R&D)-focused pharmaceutical company. The Company is engaged in the business of pharmaceuticals, which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The Company deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The Company operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.


Technical Data

50 DMA(₹)
884.64
100 DMA(₹)
835.60
200 DMA(₹)
800.95
52 Weeks Range
520.60     1,107.85

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required